These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32155165)

  • 1. Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria.
    Schmidbauer C; Schubert R; Schütz A; Schwanke C; Luhn J; Gutic E; Pirker R; Lang T; Reiberger T; Haltmayer H; Gschwantler M
    PLoS One; 2020; 15(3):e0229239. PubMed ID: 32155165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy.
    Grebely J; Dore GJ; Alami NN; Conway B; Dillon JF; Gschwantler M; Felizarta F; Hézode C; Tomasiewicz K; Fredrick LM; Dumas EO; Mensa FJ
    Int J Drug Policy; 2019 Apr; 66():73-79. PubMed ID: 30735896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.
    Schmidbauer C; Schwarz M; Schütz A; Schubert R; Schwanke C; Gutic E; Pirker R; Lang T; Reiberger T; Haltmayer H; Gschwantler M
    PLoS One; 2021; 16(6):e0252274. PubMed ID: 34086708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
    Wei L; Wang G; Alami NN; Xie W; Heo J; Xie Q; Zhang M; Kim YJ; Lim SG; Fredrick LM; Lu W; Liu W; Kalluri HV; Krishnan P; Tripathi R; Mobashery N; Burroughs M; Asatryan A; Jia J; Hou J
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):839-849. PubMed ID: 32682494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.
    Berg T; Naumann U; Stoehr A; Sick C; John C; Teuber G; Schiffelholz W; Mauss S; Lohmann K; König B; Pangerl A; Niederau C
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1052-1059. PubMed ID: 30874328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
    Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E;
    J Hepatol; 2020 Mar; 72(3):431-440. PubMed ID: 31655134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C.
    D'Ambrosio R; Pasulo L; Puoti M; Vinci M; Schiavini M; Lazzaroni S; Soria A; Gatti F; Menzaghi B; Aghemo A; Capelli F; Rumi MG; Morini L; Giorgini A; Pigozzi MG; Rossini A; Maggiolo F; Pan A; Memoli M; Spinelli O; Del Poggio P; Saladino V; Spinetti A; De Bona A; Capretti A; Uberti-Foppa C; Bonfanti P; Terreni N; Menozzi F; Colombo AE; Giglio O; Centenaro R; Borghi M; Baiguera C; Picciotto V; Landonio S; Gori A; Magnani C; Noventa F; Paolucci S; Lampertico P; Fagiuoli S;
    J Hepatol; 2019 Mar; 70(3):379-387. PubMed ID: 30472321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
    Naganuma A; Chayama K; Notsumata K; Gane E; Foster GR; Wyles D; Kwo P; Crown E; Bhagat A; Mensa FJ; Otani T; Larsen L; Burroughs M; Kumada H
    J Gastroenterol; 2019 Aug; 54(8):752-761. PubMed ID: 30868245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study.
    Nozaki A; Atsukawa M; Kondo C; Toyoda H; Chuma M; Nakamuta M; Uojima H; Takaguchi K; Ikeda H; Watanabe T; Ogawa S; Itokawa N; Arai T; Hiraoka A; Asano T; Fujioka S; Ikegami T; Shima T; Ogawa C; Akahane T; Shimada N; Fukunishi S; Abe H; Tsubota A; Genda T; Okubo H; Mikami S; Morishita A; Moriya A; Tani J; Tachi Y; Hotta N; Ishikawa T; Okanoue T; Tanaka Y; Kumada T; Iwakiri K; Maeda S;
    Hepatol Int; 2020 Mar; 14(2):225-238. PubMed ID: 32128704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
    Sezaki H; Suzuki F; Hosaka T; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Gastroenterol; 2019 Oct; 54(10):916-927. PubMed ID: 30903385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection.
    Toyoda H; Atsukawa M; Watanabe T; Nakamuta M; Uojima H; Nozaki A; Takaguchi K; Fujioka S; Iio E; Shima T; Akahane T; Fukunishi S; Asano T; Michitaka K; Tsuji K; Abe H; Mikami S; Okubo H; Okubo T; Shimada N; Ishikawa T; Moriya A; Tani J; Morishita A; Ogawa C; Tachi Y; Ikeda H; Yamashita N; Yasuda S; Chuma M; Tsutsui A; Hiraoka A; Ikegami T; Genda T; Tsubota A; Masaki T; Tanaka Y; Iwakiri K; Kumada T
    J Gastroenterol Hepatol; 2020 May; 35(5):855-861. PubMed ID: 31609495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.
    Akiyama MJ; Norton BL; Arnsten JH; Agyemang L; Heo M; Litwin AH
    Ann Intern Med; 2019 May; 170(9):594-603. PubMed ID: 30959528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.
    Flamm S; Reddy KR; Zadeikis N; Hassanein T; Bacon BR; Maieron A; Zeuzem S; Bourliere M; Calleja JL; Kosloski MP; Oberoi RK; Lin CW; Yu Y; Lovell S; Semizarov D; Mensa FJ
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):527-535.e6. PubMed ID: 30012435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience.
    Ueda Y; Kobayashi T; Ikegami T; Miuma S; Mizuno S; Akamatsu N; Takaki A; Ishigami M; Takatsuki M; Sugawara Y; Maehara Y; Uemoto S; Seno H
    J Gastroenterol; 2019 Jul; 54(7):660-666. PubMed ID: 30806783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
    Suda G; Hasebe C; Abe M; Kurosaki M; Itakura J; Izumi N; Uchida Y; Mochida S; Haga H; Ueno Y; Abe K; Takahashi A; Ohira H; Tsukuda Y; Furuya K; Baba M; Yamamoto Y; Kobayashi T; Inoue J; Terasita K; Ohara M; Kawagishi N; Izumi T; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
    J Gastroenterol; 2019 Jul; 54(7):641-649. PubMed ID: 30778716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy.
    Ohya K; Imamura M; Osawa M; Teraoka Y; Morio K; Fujino H; Ono A; Nakahara T; Murakami E; Yamauchi M; Kawaoka T; Hiramatsu A; Tsuge M; Aikata H; Hayes CN; Chayama K
    Clin J Gastroenterol; 2020 Apr; 13(2):267-270. PubMed ID: 31463795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
    Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
    J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study.
    Feld JJ; Cypel M; Kumar D; Dahari H; Pinto Ribeiro RV; Marks N; Kamkar N; Bahinskaya I; Onofrio FQ; Zahoor MA; Cerrochi O; Tinckam K; Kim SJ; Schiff J; Reichman TW; McDonald M; Alba C; Waddell TK; Sapisochin G; Selzner M; Keshavjee S; Janssen HLA; Hansen BE; Singer LG; Humar A
    Lancet Gastroenterol Hepatol; 2020 Jul; 5(7):649-657. PubMed ID: 32389183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection.
    Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews GV
    Hepatology; 2020 Jul; 72(1):7-18. PubMed ID: 31652357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies.
    Foster GR; Dore GJ; Wang S; Grebely J; Sherman KE; Baumgarten A; Conway B; Jackson D; Asselah T; Gschwantler M; Tomasiewicz K; Aguilar H; Asatryan A; Hu Y; Mensa FJ
    Drug Alcohol Depend; 2019 Jan; 194():487-494. PubMed ID: 30529905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.